Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2021

Year

David Ishola, Daniela Manno, Muhammed O. Afolabi, Babajide Keshinro, Viki Bockstal, Baimba Rogers, Kwabena Owusu-Kyei, Alimamy Serry-Bangura, Ibrahim Swaray, Brett Lowe,

The Lancet Infectious Diseases

VaccinationVaccine SafetyTwo-dose Heterologous Ad26.zebovVaccine DevelopmentEmerging Infectious DiseasesVaccine TestingVaccine EfficacySierra LeoneInfection ControlStage 2MedicineVaccine ResearchEpidemiology